Cita APA

JE, A., J, B., P, S., FJ, S. B., JÁ, G. S., I, P., . . . A, L. (2024). Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.

Citación estilo Chicago

JE, Alés-Martínez, et al. Olaparib Plus Trastuzumab in HER2-positive Advanced Breast Cancer Patients With Germline BRCA1/2 Mutations: The OPHELIA Phase 2 Study. 2024.

Cita MLA

JE, Alés-Martínez, et al. Olaparib Plus Trastuzumab in HER2-positive Advanced Breast Cancer Patients With Germline BRCA1/2 Mutations: The OPHELIA Phase 2 Study. 2024.